期刊文献+

丙酸氟替卡松/沙美特罗干粉剂联合脱敏疗法治疗尘螨过敏性哮喘的效果 被引量:1

Effect of fluticasone propionate/salmeterol dry powder combined with desensitization therapy on treating allergic asthma due to dust mite
下载PDF
导出
摘要 目的观察丙酸氟替卡松/沙美特罗干粉剂联合脱敏疗法治疗尘螨过敏性哮喘的临床疗效与安全性。方法选择2012年1月-2014年2月我院诊治的符合诊断标准的112例哮喘患者,根据不同治疗方法将其分为观察组(n=58)和对照组(n=54)。常规治疗后,对照组吸入丙酸氟替卡松/沙美特罗干粉剂(50μg/250μg);观察组在此基础上加用脱敏疗法。观察两组患者治疗1年后的疗效和肺功能指标。结果观察组临床疗效、总控制率、治疗后FEV1/FVC、PEF、症状评分均优于对照组;观察组复发率低于对照组,差异有统计学意义(P〈0.05)。两组患者治疗过程中无严重不良反应。结论丙酸氟替卡松/沙美特罗联合脱敏疗法治疗过敏性哮喘效果理想,且安全性高,值得推广应用。 Objective To observe the clinical efficacy and safety of fluticasone propionate/salmeterol dry powder combined with desensitization therapy for allergic asthma due to dust mite. Methods 112 patients with asthma who were diagnosed and treated in our hospital from January 2012 to February 2014 were selected and diagnosed according to the criteria of diagnosis and treatment,and were divided into observation group(n=58) and control group(n=54).After conventional treatment,fluticasone propionate/salmeterol dry powder(50 μg/250 μg) was inhaled in the control group,while in the observation group,on the basis of the control group,desensitization therapy was added.The efficacy and pulmonary function after one-year treatment were observed. Results The clinical efficacy,overall control rate,FEV1/FVC after treatment,peak expiratory flow(PEF),and symptom scores was better than that in the control group respectively.Recurrence rate in the observation group was lower than that in the control group,with statistical differences(P〈0.05).No severe adverse reaction occurred during treatment. Conclusion Dry powder of fluticasone propionate/salmeterol combining with desensitization therapy can obtain an ideal effect on treating allergic asthma in high safety,which is worthy of expansive application.
作者 邝敏
出处 《中国当代医药》 2016年第5期14-16,共3页 China Modern Medicine
基金 广西壮族自治区南宁市科学研究与技术开发计划项目(20133181)
关键词 丙酸氟替卡松/沙美特罗 脱敏疗法 支气管哮喘 PEF FEV1/FVC Fluticasone propionate/salmeterol Desensitization therapy Bronchial asthma Peak expiratory flow FEV1/FVC
  • 相关文献

参考文献13

二级参考文献58

  • 1王晋舜.咳嗽变异性哮喘诊治探讨[J].临床肺科杂志,2006,11(3):369-369. 被引量:46
  • 2董宗祈,陈孝萍,袁雄伟.咳嗽变异性哮喘71例临床分析[J].中国实用儿科杂志,1996,11(6):368-368. 被引量:107
  • 3辛建保,向敏,陶晓南,彭毅,张瑞祥.咳嗽变异性哮喘与典型哮喘患者气道高反应性的比较[J].中华医学杂志,1997,77(1):70-71. 被引量:15
  • 4韩虹,陈少华,邱前辉.安脱达尘螨疫苗治疗变应性鼻炎的疗效及安全性评价[J].广东医学,2007,28(6):991-992. 被引量:9
  • 5中华医学会呼吸病学分会.哮喘组支气管哮喘防治指南[J].中华结核和呼吸杂志,2008,31(3):177-185.
  • 6Pauwels RA, Pedersen S, Busse WW, et al. START Investigation Group. Early intervention with budesonide in mild persistent asthma : a randomized, double blind trial. Lancet, 2003,361 : 1071 - 1076.
  • 7OByrne PM, Bisgard H, Gohart PP, et al. Budesonide/Formoterol combination Therapy as Both Maintenance and Reliever Medication in Asthma. Am J Respir Crit Care Med,2004,171 : 129 - 136.
  • 8Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budenoside on exacerbation of asthma: Formoterol And Corticosteroids Establishing Therapy [ FACET ] International study Group. N Eng J Med, 1997,337 : 1405 - 1411.
  • 9OByrne PM, Barnes PJ, Rudriguoz-Rosin R, et al. Tow dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med,2001,164: 1392 - 1397.
  • 10Bateman ED, Bousley HA, Bousquet J, et al. Can Guideline-defined Asthma Control be achieved. The Gaining Optimal Asthma Control Study (GOAL). Am J Respir Crit Care Med,2004,170: 836 - 844.

共引文献6095

同被引文献10

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部